Cardiotoxicity associated with oncological chemotherapy: Identification of risk factors
DOI:
https://doi.org/10.33448/rsd-v10i2.12299Keywords:
Neoplasms; Clinical Protocol; Risk Factors; Cardiotoxicity.Abstract
Objective: To identify the risk factors for cardiotoxicity in cancer patients undergoing antineoplastic treatment. Methodology: Integrative literature review, performed in the MEDLINE/PUBMED, SCIELO AND VHL databases, by crossing the descriptors: neoplasms, clinical protocols, risk factors and cardiotoxicity and their respective interconnected terms by the Boolean operators “AND” and “OR”, with a time frame from 2017 to 2019). Results: After reading and analyzing the works (n: 30) found, seven categories emerged: Overweight and obesity; cardiac arrhythmias; preexisting disease, mediastinal irradiation, genetic predisposition; physical inactivity; systolic arterial hypertension, diabetes, dyslipidemia and smoking; long therapy time and cumulative dose; association of chemotherapy classes. Conclusion: Many risk factors are present in cancer patients, thus contributing to the development of cardiotoxicity. Accordingly, it is essential that oncological nursing has, in its practice, focus on early identification of them, in order to prevent and control cardiotoxicity.
References
Adão, R., et al (2013). Cardiotoxicidadeassociadaàterapê uticaoncológica:mecanismosfisiopatológicoseestratégiasdeprevenc ?ão. Revista Portuguesa de Cardiologia, 32(5), 395-409. https://doi.org/x.doi.org/10.1016/j.repc.2012.11.002
Antunes, P., et al (2019). Impact of exercise training on cardiotoxicity and cardiac health outcomes in women with breast cancer anthracycline chemotherapy: a study protocol for a randomized controlled trial. Trials, 20(1), 1-11. https://doi.org/doi.org/10.1186/s13063-019-3499-9
Bergamini, C., et al (2019). Role of Speckle Tracking Echocardiography in the Evaluation of Breast Cancer Patients Undergoing Chemotherapy: Review and Meta-analysis of the Literature. Cardiovascular Toxicology, 19(6), 485-492. https://doi.org/10.1007/s12012-019-09523-y
Bittar, Cristina Salvadori , & Fonseca, Silvia Moulin Ribeiro . (2017, November). RADIOTERAPIA E CARDIOTOXICIDADE. Rev Soc Cardiol Estado de São Paulo, 4(29), 274-277. https://doi.org/http://dx.doi.org/10.29381/0103-8559/20172704274-7
Cameron, D., et al. (2017). 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet, 389(10075), 1195-1205.
Conte, P., Frassoldati, A, Bisagni, G., Brandes, A. A., Donadio, M., Garrone, Ó., Piacentini, F., Cavanna, L., Giotta, F., Aieta, M., Gebbia, V., Molino, A., musolino, U. M., Ferro, A., Maltoni, R., Danese, S., Zamagni, C., Rimanti , A., Cagossi, K., Russo, U. M., Pronzato, P., Giovanardi, F., Moretti, G., Lombardo, L., Schirone, A., Beano, A., Amaducci, L., Bajardi, E. A., Vicini , R., Balduzzi, S , D'Amico , R., & Guarneri, V . (2018). Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study. Annals Of Oncology, 29(12), 2328-2333. https://doi.org/10.1093/annonc/mdy414
Corrêa, M. V. dos S. , Chermont, S. L. S. M. da C., Marinho, T. A. S., & Quintão, M. M. P. (2019). Importância da Prática de Atividade Física para Prevenção do Risco de Cardiotoxicidade: Revisão Sistemática. Revista Brasileira de Cancerologi, 65(3), 1-10. https://doi.org//doi.org/10.32635/2176-9745.RBC.2019v65n3.433
Cruz, M., Rodrigues, J. D., & Campelo, M. (2016). Cardiotoxicidadenaterapêuticacomantraciclinas:estratégiasdeprevenc ?ão. Revista Portuguesa de Cardiologia, 35(6), 359-371. https://doi.org/x.doi.org/10.1016/j.repc.2015.12.004
Departamento de Atenção Básica., Ministério da Saúde. Secretaria de Atenção à Saúde. (2013). Diretrizes para o cuidado das pessoas com doenças crônicas nas redes de atenção à saúde e nas linhas de cuidado prioritárias. Ministério da Saúde. https://bvsms.saude.gov.b r/bvs/publicacoes/diretrizes%20_cuidado_pessoas%20_doencas_cronicas.pdf
Dessalvi, C. C., et al (2018). Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention. Journal Of Cardiovascular Medicine, 19(7), 315-323. https://doi.org/10.2459/JCM.0000000000000667
Diretriz Brasileira de Cardio- Oncologia da Sociedade Brasileira de Cardiologia. (2020). Sociedade Brasileira de Cardiologia, 1-38. http://abccardiol.org/wp-content/uploads/articles_xml/1678-4170-abc-115-05-1006/1678-4170-abc-115-05-1006.x64000.pdf
Estimativa 2020: incidência de câncer no Brasil / Instituto Nacional de Câncer. (2019). INCA. https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2020-incidencia-de-cancer-no-brasil.pdf
European Heart Journal. (2016). ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: ?The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC), 2768-2801. https://academic.oup.com/eurheartj/article/37/36/2768/2197413
Lynce, F., Barac, A., Geng, X., Dang, C., Yu, A., Smith, K., G allagher, C., Pohlmann, P., Nunes, R., & Herbolsheimer, P.Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Research And Treatment, 175(3), . 595-603. https://doi.org/doi: 10.1007 / s10549-019-05191-2.
Folha informativa ? Câncer. (2018). OPAS BRASIL. https://www.paho.org/bra/index.php?option=com_content&view=article&id=5588:folha-informativa-cancer&Itemid=1094
G. Kaboré , E., et al. (2019). Association of body mass index and cardiotoxicity related to anthracyclines and trastuzumab in early breast cancer: French CANTO cohort study. Plos Medicine, 16(12), 1-12. https://doi.org/doi.org/10.1371/journal.pmed.1002989 D
Ganz, P. A., et al (2010). Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. Journal Of Clinical Oncology, 35(35), 3942-3948. https://doi.org/DOI: https://doi.org/10.1200/JCO.2017. 74.1165
Gavila, J., Segui, M. A., Calvo, L., López, T., Alonso, J. J., Farto, M., & Rosa, R., Sa´nchez-de la . (2016). Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study. Clinical And Translational Oncology, 19(1), 91?104. https://doi.org/DOI 10.1007/s12094-016-1508-y
Gong, I. Y., et al. Early diastolic strain rate measurements by cardiac MRI in breast cancer patients treated with trastuzumab: a longitudinal study. The International Journal Of Cardiovascular Imaging, 35(4), 653-662. https://doi.org/DOI: 10.1007/s10554-018-1482-2
Gori, S., et al. When and how to treat women with HER2-positive, small (pT1a-b), nodenegative breast cancer? Critical Reviews In Oncology/hematology, 128, 130-138. https://doi.org/doi.org/10.1016/j.critrevonc.2018.03.010
Heck, S. L., et al (2018). Effect of candesartan and metoprolol on myocardial tissue composition during anthracycline treatment: the PRADA trial. European Heart Journal - Cardiovascular Imaging, 19(5), 544-552. https://doi.org/10.1093/ehjci/jex159
Heron, M., & Anderson, R. N. (2016, August). Mudanças na causa principal de morte: padrões recentes em Doença cardíaca e mortalidade por câncer. de Controle e Prevenção de Doenças, 254, 1-8. file:///D:/Meus%20Documentos/Downloads/dados%20epidemiol%C3%B3gicos.en.pt.pdf
Inno, A., et al.(October). One year versus a shorter duration of adjuvant trastuzumab for HER2-positive early breast cancer: a systematic review and meta-analysis. Breast Cancer Research And Treatment, 173(2), 247-254. https://doi.org/10.1007/s10549-018-5001-x
Karvelas, G., et al. (July). Everolimus as cancer therapy: Cardiotoxic or an unexpected antiatherogenic agent? A narrative review. Hellenic Journal Of Cardiology, 59(4), 196-200.
Köche, J. K. (2011). Fundamentos de metodologia científica: teoria da ciência e iniciação à pesquisa (ed. Original). Vozes. http://www.brunovivas.com/wp-content/uploads/sites/10/2018/07/K%C3%B6che-Jos%C3%A9-Carlos0D0AFundamentos-de-metodologia-cient%C3%ADfica-_- teoria-da0D0Aci% C3% AAncia-e-inicia% C3% A7% C3% A3o-% C3% A0-pesquisa.pdf
Kuruc, J. C., Archibold, A. A. D., Motta, J., Rao, K. S., Trachtenberg, B., Ramos, C., Wang, H., Gorenstein, D., Vannberg, F., & Jordan, K. (2019). Desenvolvimento de cardiomiopatia dilatada induzida por antraciclina por mutação no gene LMNA em paciente com câncer de mama: relato de caso. BMC Cardiovascular Disorders , 19 (1), 1-5. https://doi.org/10.1186/s12872-019-1155-7
Li, J., & Gu, J. (2018). Cardiovascular Toxicities with Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of 77 Randomized Controlled Trials. Clinical Drug Investigation, 38(12), 1109-1123. https://doi.org/10.1007/s40261-018-0709-2
Lin, K., & Lengacher, C. A . (2019). Anthracycline Chemotherapy-Induced Cardiotoxicity in Breast Cancer Survivors: A Systematic Review. Oncol Nurs Forum, 46(5), 145-158. https://doi.org/10.1188/19.ONF.E145-E158
Lins de Barros, M. V., et al (2018). Left Ventricular Regional Wall Motion Abnormality is a Strong Predictor of Cardiotoxicity in Breast Cancer Patients Undergoing Chemotherapy. Arquivos Brasileiros de Cardiologia, 50-56. https://doi.org/10.5935/abc.20180220
Nowsheen, S., et al (2018). Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction. Journal Of The American Heart Association, 7(15), 1-12. https://doi.org/doi: 10.1161/JAHA.118.008637
Pereira, A. S., Shitsuka, D. M., Parreira, F. J, & Shitsuka, R. (2018). Metodologia da Pesquisa Científica. UAB / NTE / UFSM. https://repositorio.ufsm.br/bitstream/handle/1/15824/Lic_Computacao_Metodologia-Pesquisa-Cientifica.pdf?sequence=1
Pina, L. C. de O., et al. Cardiotoxicidade nas Terapias Neoadjuvante e Adjuvante do Câncer de Mama. Revista Brasileira de Cancerologia, 65(3), 1-8. https://doi.org/doi: https://doi.org/10.32635/2176-9745.RBC.2019v65n3.404
Ponde, N., et al. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)., 168(3), 631-638.
Reinbolt , R. E., et al. (2015). Risk factors for anthracycline-associated cardiotoxicity. Supportive Care In Cancer, 24(5), 2173-2180. https://doi.org/doi: 10.1007/s00520-015-3008-y
Sánchez, M. D., & Milián, M. B. (2020). Sinais elétricos de arritmias ventriculares malignas e morte súbita .: importância em pacientes recebendo terapia anticâncer. Revista Cubana do Cardiologia y Cirurgia Cardiovascular, 23(15), 1-5. file:///D:/Meus%20Documentos/Downlo ads/arrtimia%20fator%20de%20risco.es.pt.pdf
Sharalaya, A., & Collier, P. (2018). Prevention of Cardiotoxicities With Traditional and Novel Chemotherapeutic Agents. Current Heart Failure Reports, 5(4), 260-269. https://doi.org/DOI: 10.1007/s11897-018-0400-1
Siewert, J. S., Rodrigues, D. B., de Malfussi, L. B. H., de Andrade, S. R., & Erdmann, A. L. (2017). Gestão do Cuidado Integral em Enfermagem: Reflexões sob a Perspectiva do Pensamento Complexo. Revista Mineira de Enfermagem , 21 , 1-5.
Stephen J., ey al (2019). Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy. Medicine & Science In Sports & Exercise, 51(8), 1573-1581. https://doi.org/doi: 10.1249/MSS.0000000000001970
Swain, S. M., et al (2018). Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study. Annals Of Oncology, 29(3), 646-653. https://doi.org/10.1093/annonc/mdx773
Turato, Egberto Ribeiro. (2019). Tratado da pesquisa clínico- qualitativa: contrução teórico-epistemológica, discussão comparada e aplicação nas áreas de saúde e humana. (3ª reimpressão). Vozes.
Yaylali , Y. T., et al (2016). Atrial Function in Patients with Breast Cancer After Treatment with Anthracyclines. Arquivos Brasileiros de Cardiologia, 411-419. https://doi.org/10.5935/abc.20160146
Yuan, M., et al (2018). The incidence of atrial fibrillation with trastuzumab treatment: A systematic review and meta-analysis. Cardiovascular Therapeutics, 36(6), 12475-1280. https://doi.org/10.1111/1755-5922.12475
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Paloma Geralda Mizael de Paula Silva; Vanessa Galdino de Paula; Luana Ferreira de Almeida; Eloá Carneiro Carvalho; Thereza Christina Mó y Mó Loureiro Varella; Samira Silva Santos Soares; Norma Valéria Dantas de Oliveira Souza; Sandra Regina Maciqueira Pereira; Karla Biancha Silva de Andrade
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
